Pharm J), 2001, **36**(1): 49-51.

[7] Yao M G, Qi Y, Bi K S, *et al*. A precolumn derivatization high-performance liquid chromatographic method with improved sensitivity and specificity for the determination of astragaloside Ⅳ in radix astragali [J]. *J Chromatogr Sci*, 2000, **38**(8): 325-328.

[8] 奚念朱(Xi N Z)编. 药剂学[M]. 第3版. 北京: 人民卫生出版社, 1997. 468-468.

Determination and Pharmacokinetical Study of Astragaloside Ⅳ in Rats Urine by HPLC-MS

GU Yong-Chuan, WANG Guang-Ji

Center of Pharmacokinetics, China Pharmaceutical University, Nanjing 210009

ABSTRACT **AIM** The purpose is to develop a new method for the determination of Astragaloside Ⅳ in rat's urine. **METHODS** The HPLC-MS method utilizing solid phase extraction was established to determine the concentration of Astragaloside Ⅳ in rat's urine. The analysis was carried on Diamonsil(*tm*) C_{18} column (4.6× 250 mm, 5 μm). The mobile phase was CH_3CN-H_2O (40∶60, v/v), with flow rate 0.8 ml/min, electrospray MS detector. **RESULTS** The calibration curve was linear (r=0.9991, n=5) in the range of 0.1~10 μg/ml for Astragaloside Ⅳ. The limit of detection (LOD) was 10 ng/ml. The average recovery was 91.63% and RSD of intra-day and inter-day was smaller than 10%. This method was applied to the determination of ASI in rats and the pharmacokinetical parameters were calculated as follows: k=0.27 h^{-1}, ke=2.5× $10^{-2}h^{-1}$. **CONCLUSION** A reliable HPLC-MS assay for Astragaloside Ⅳ was developed. The assay method was appropriate for determination of Astragaloside Ⅳ in rat's urine.

KEY WORDS Astragaloside Ⅳ; Solid phase extraction; HPLC-MS; Excretion Pharmacokinetics

---

中国医药论坛——WTO 与中国医药市场高层报告会

2002 年5 月 20 日, "中国医药论坛—WTO 与中国医药市场高层报告会" 在京举行。会议由中国医药企业管理协会主办, 世界贸易组织 WTO 一副总干事曼多查先生(Miguel Rodriguez Mendoza)、联合国贸易和发展会议项目主任佩多·洛夫先生(Pedro Roffe)分别作了"中国医药市场开放后企业家的战略思考"和"与贸易相关的知识产权保护规划与医药知识产权保护"的报告, 就入世对中国医药企业的机遇与挑战以及 WTO 的基本规则与贸易争端的解决等相关问题作精彩讲演。国家药品监督管理局副局长桑国卫、国家经贸委经济运行局副局长于明德等也参加了有关 WTO 与中国医药产业前景的讨论。桑国卫副局长作了"加入 WTO 与中国的药品监督管理"的报告。

在经济全球化的背景下, 医药产业界的这次盛会显得意义深远, 它标志着我国医药界在加入 WTO 的元年已开始从实际着手寻找更多的机会。

(源于《医药经济报》)